Alluvi Glow 70mg

The Alluvi Glow 70mg is Britain’s most advanced tri-peptide cellular repair pen — a precision-engineered research formulation combining BPC-157 10mg, TB500 10mg, and GHK-Cu 50mg in a single pre-filled injection pen. Developed by Alluvi Healthcare, the UK’s most trusted Synedica-certified peptide supplier, the Glow 70mg pen delivers the most studied skin, hair, and cellular repair peptides in one convenient, laboratory-ready format. Whether you are investigating collagen synthesis pathways, angiogenic signalling, or multi-peptide cytoprotective mechanisms, the Alluvi Glow 70mg pen is the definitive UK research tool for regenerative peptide science.

Where comparable UK suppliers offer single-peptide vials that require individual reconstitution, weighing, and handling, the Alluvi Glow pen arrives pre-filled, cold-chain dispatched within 48 hours, and accompanied by a full Certificate of Analysis confirming ≥98% purity across all three active compounds. For UK researchers who demand accuracy, traceability, and convenience in one product, there is no equivalent on the British market.

Product Specifications

Product Name	Alluvi Glow 70mg — Tri-Peptide Cellular Repair Pen
Active Compounds	BPC-157 (10mg) · TB500 (10mg) · GHK-Cu (50mg)
Total Peptide Content	70mg per pack (2 pens × 5mg per pen)
Purity	≥98% — verified by independent COA
Format	Pre-filled subcutaneous injection pen — solution for injection
Storage	Refrigerate 2°C – 8°C. Do not freeze. Keep away from light.
Dispatch	48-hour UK cold-chain dispatch · Free tracked delivery
COA Included	Yes — full third-party Certificate of Analysis
Research Classification	For laboratory and scientific research use only — not for human consumption

Why the Alluvi Glow 70mg Pen Stands Alone in UK Research

The regenerative peptide research field has long recognised BPC-157, TB500 (Thymosin Beta-4 fragment), and GHK-Cu as three of the most extensively documented bioactive peptides in preclinical science. Individually, each has accumulated decades of peer-reviewed literature demonstrating distinct and reproducible mechanisms across wound healing, angiogenesis, extracellular matrix remodelling, and cellular stress response models. The scientific rationale for combining all three into a single formulation — the so-called “GLOW blend” — lies in the hypothesis that their complementary molecular entry points may produce additive or synergistic effects in controlled experimental settings.

The Alluvi Glow 70mg makes this research accessible to UK laboratories without the complexity of sourcing, preparing, and quality-verifying three separate peptide compounds. With a total of 70mg across three actives — the highest-density GLOW formulation available in the UK — delivered in a ready-to-use pre-filled pen format, it is the most complete cellular repair peptide research tool on the British market.

Unlike unverified powders from unregulated overseas suppliers, every Alluvi Glow pen is dispatched cold-chain from UK stock, accompanied by a third-party Certificate of Analysis confirming ≥98% purity for all three peptide compounds. This level of verification is non-negotiable for reproducible research outcomes — and it is what separates Alluvi Healthcare from every other peptide pen UK supplier currently operating.

BPC-157 10mg — Cytoprotection & Nitric Oxide Pathway Research

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide — a 15-amino acid fragment — originally isolated from mammalian gastric juice. It is among the most heavily studied research peptides in regenerative biology, with over three decades of preclinical investigation exploring its role in nitric oxide pathway modulation, growth factor signalling, extracellular matrix remodelling, and cytoprotection under cellular stress conditions.

A 2024 systematic review published in PubMed Central examined 36 studies spanning 1993 to 2024, concluding that BPC-157 consistently demonstrates pro-healing activity across musculoskeletal injury models by upregulating growth factors and modulating inflammatory signalling cascades. In the context of the Alluvi Glow 70mg formulation, BPC-157 contributes primarily to cytoprotective pathway research — particularly the stabilisation of nitric oxide signalling, reduction of oxidative stress markers, and support of mucosal and connective tissue integrity in preclinical models.

BPC-157 also plays a key role in angiogenesis research within the GLOW blend context — stimulating VEGF expression and promoting granulation tissue formation, which represents the early scaffold of tissue repair in wound models. Its high stability in biological environments and rapid systemic distribution in animal models make it a reliable and reproducible research compound for multi-pathway experimental designs.

TB500 10mg — Actin Dynamics, Cell Migration & Tissue Remodelling

TB500 is a synthetic 43-amino acid peptide corresponding to the active region of Thymosin Beta-4 — a highly conserved, actin-binding protein involved in cytoskeletal organisation, cellular migration, and intracellular transport. TB500 retains both the actin-sequestering properties of full-length Thymosin Beta-4 and its secondary function as a regulator of gene expression and inflammatory signalling, making it one of the most mechanistically rich peptides in regenerative research.

In the context of the Alluvi Glow 70mg formulation, TB500’s primary research contribution is cytoskeletal support — promoting the actin polymerisation that enables fibroblasts, keratinocytes, and endothelial cells to migrate effectively to injury sites. This cell recruitment function represents a distinct molecular entry point from BPC-157’s nitric oxide and growth factor pathways, which is precisely the scientific rationale for combining them: TB500 facilitates early cellular mobilisation while BPC-157 and GHK-Cu support downstream repair and remodelling processes.

TB500 also modulates PI3K/Akt and NF-κB-associated signalling cascades — pathways involved in angiogenesis, cytokine production, and the transition from acute inflammation to tissue remodelling. By mobilising endothelial progenitor cells and facilitating vascular remodelling, TB500 complements GHK-Cu’s VEGF upregulation to create a dual angiogenic stimulus within the GLOW blend — a convergence that represents a compelling research hypothesis for studies investigating coordinated vascular repair in ischaemic or wounded tissue models.

GHK-Cu 50mg — Collagen Synthesis, Antioxidant Defence & Skin Repair Research

GHK-Cu (Glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Its concentration declines significantly with age, a decline that has been correlated in research literature with reduced skin repair capacity, increased oxidative stress, and diminished extracellular matrix integrity. At 50mg — representing 71% of the total peptide content in the Alluvi Glow 70mg pen — GHK-Cu is the dominant compound in this formulation, reflecting its broad research application across dermatology, wound healing, and anti-ageing biology.

GHK-Cu is extensively documented for its ability to stimulate collagen and glycosaminoglycan synthesis, enhance angiogenesis via VEGF upregulation, and modulate hundreds of genes linked to skin regeneration, anti-ageing, and extracellular matrix maintenance. It acts simultaneously as a potent antioxidant — chelating free copper ions and downregulating pro-inflammatory cytokines including TNF-α and IL-6 — and as a metalloproteinase regulator, increasing tissue remodelling enzyme activity while simultaneously upregulating anti-protease expression to prevent uncontrolled matrix degradation.

In preclinical wound models using New Zealand white rabbits, GHK-Cu exposure demonstrated superior tissue organisation and repair-associated outcomes relative to comparator groups, supporting its continued investigation as a peptide-metal complex in extracellular matrix signalling research. A separate investigation comparing GHK-Cu with helium-neon laser stimulation in similar models found that GHK-Cu-exposed groups showed markers linked to reduced neutrophil-associated inflammatory responses alongside increased vascular formation indicators — a finding that positions it as a strong candidate for combined anti-inflammatory and angiogenic research protocols.

For UK researchers investigating skin repair biology, hair follicle signalling, collagen pathway modulation, or age-associated extracellular matrix decline, the 50mg GHK-Cu content of the Alluvi Glow 70mg pen represents the most concentrated, COA-verified source of this peptide available from a UK supplier. Explore the broader Alluvi Healthcare research peptide range for complementary compounds to build multi-peptide experimental protocols.

The GLOW Blend: Synergistic Tri-Peptide Research Design

The scientific rationale for the GLOW formulation is rooted in the complementarity of the three peptides’ molecular mechanisms rather than functional redundancy. BPC-157, TB500, and GHK-Cu each modulate distinct — yet overlapping — biological pathways, creating a research model that enables simultaneous investigation of nitric oxide signalling, actin cytoskeletal dynamics, copper-mediated redox regulation, extracellular matrix remodelling, and multi-pathway angiogenesis within a single experimental framework.

The key mechanistic convergences in the Alluvi Glow 70mg research model include:

Pathway	BPC-157	TB500	GHK-Cu
Angiogenesis	VEGF upregulation	Endothelial progenitor mobilisation	VEGF + capillary density
Inflammation	NO pathway stabilisation	Macrophage/neutrophil modulation	TNF-α / IL-6 downregulation
ECM Remodelling	Granulation tissue formation	Fibroblast migration	Collagen / GAG synthesis
Oxidative Stress	Oxidative stress reduction	Cytokine signalling modulation	Redox regulation / antioxidant enzymes
Cell Migration	Epithelial cell proliferation	Actin polymerisation / cytoskeletal support	Keratinocyte / fibroblast activation

This multi-pathway convergence is why the GLOW blend has become one of the most widely referenced tri-peptide research formulations in regenerative biology. The Alluvi Glow 70mg pen delivers this formulation in the highest-purity, most convenient format available to UK researchers — removing the logistical barriers of multi-compound sourcing while maintaining the analytical rigour that reproducible research demands.

Research Applications: Alluvi Glow 70mg

The Alluvi Glow 70mg pen is appropriate for laboratory research programmes investigating the following areas:

Skin & Dermatological Research: GHK-Cu’s well-documented role in collagen I and III synthesis, elastin production, skin elasticity markers, and wound closure kinetics makes the Glow 70mg pen a primary research tool for dermatological repair model studies. Preclinical data consistently associates GHK-Cu exposure with improvements in skin firmness, reduced oxidative markers, and enhanced wound healing rates — areas that remain active fields of investigation in academic and pharmaceutical research settings.

Hair Follicle Biology: GHK-Cu has been investigated for its potential role in hair follicle stimulation and keratinocyte activation. Combined with TB500’s cytoskeletal support for cell migration and BPC-157’s angiogenic VEGF upregulation — which improves follicular blood supply — the Alluvi Glow formulation provides a multi-mechanism research model for hair biology studies.

Tissue Repair & Wound Healing Models: The complementary angiogenic, anti-inflammatory, and ECM-remodelling mechanisms of the three-peptide blend create a comprehensive research model for wound repair biology — from early cellular mobilisation through to organised matrix deposition and vascular restoration.

Cellular Stress & Cytoprotection: BPC-157 and GHK-Cu both demonstrate cytoprotective activity in models of oxidative and inflammatory cellular stress — positioning the Glow blend as a research tool for investigating protective mechanisms in tissue degeneration and age-associated cellular decline models.

Angiogenesis & Vascular Biology: The dual VEGF-stimulating activity of BPC-157 and GHK-Cu, combined with TB500’s endothelial progenitor cell mobilisation, creates a uniquely potent angiogenic research formulation for studies in vascular remodelling, ischaemic tissue recovery, and neovascularisation models.

Multi-Pathway Signalling Analysis: For researchers designing experimental protocols that require simultaneous investigation of nitric oxide, actin cytoskeletal, and copper-mediated redox pathways, the Alluvi Glow 70mg pen eliminates the need for three separate compounds — simplifying protocol design, reducing preparation variables, and improving experimental consistency.

Why UK Researchers Choose Alluvi Healthcare

Alluvi Healthcare was founded on a single principle: UK researchers deserve the same standard of peptide quality, traceability, and service that leading international suppliers provide — delivered from domestic UK stock, without the cold-chain risks, import delays, and customs uncertainty associated with overseas procurement. The Alluvi Glow 70mg pen is the most complete expression of that principle: a tri-peptide research formulation of unmatched UK purity, prepared to Synedica-equivalent standards, and dispatched within 48 hours to any UK address.

What makes Alluvi Healthcare the definitive UK peptide pen supplier:

✦ ≥98% purity guaranteed — independently verified by third-party Certificate of Analysis included with every order

✦ Pre-filled pen format — no reconstitution, no weighing, no bacteriostatic water — research-ready from the refrigerator

✦ Cold-chain 48hr UK dispatch — temperature-controlled packaging from UK stock, maintaining peptide integrity from warehouse to laboratory

✦ Full traceability — every batch traceable from synthesis to dispatch, meeting the documentation standards that serious research requires

✦ Highest-density GLOW formulation in the UK — 70mg total peptide content across BPC-157, TB500, and GHK-Cu in a single pen format

✦ Expert UK research support — our team is available via WhatsApp for product selection, storage guidance, and research protocol queries

Storage & Handling Guidelines

The Alluvi Glow 70mg pen contains a solution-for-injection formulation that requires appropriate storage conditions to maintain peptide stability and research integrity:

Temperature: Store refrigerated between 2°C and 8°C. Do not freeze. Do not expose to temperatures above 25°C.

Light: Keep away from direct light and UV exposure. Store in original packaging.

Handling: Read the package leaflet before use. For subcutaneous injection application in research settings only.

Shelf life: Use before the expiry date printed on the packaging. Do not use if the solution appears cloudy or contains particulates.

Explore the Full Alluvi Healthcare Research Range

The Alluvi Glow 70mg pen sits alongside the Alluvi Retatrutide 40mg Pen — Britain’s most trusted Synedica retatrutide 40mg pen — and the Alluvi Retatrutide 20mg Pen as part of the most comprehensive UK research peptide pen range available from a single, verified domestic supplier. For researchers building multi-compound protocols, our team can advise on research-appropriate product combinations via our contact page or WhatsApp.

Browse the complete Alluvi Healthcare shop for the full range of UK research peptide pens. All products are dispatched cold-chain from UK stock with COA documentation, free tracked delivery, and 48-hour dispatch. Read more about our quality standards and research commitments on the About Alluvi Healthcare page.

Key Research References

The following peer-reviewed and clinical sources underpin the research rationale for the BPC-157, TB500, and GHK-Cu compounds in the Alluvi Glow 70mg formulation:

• Sikiric P et al. (2018). BPC-157 and nitric oxide/growth factor pathway modulation. Current Pharmaceutical Design, 24(18):2002–2030. PubMed

• Goldstein AL et al. (2007). Thymosin Beta-4 and tissue remodelling. Annals of the New York Academy of Sciences, 1112:148–154. PubMed

• Pickart L & Margolina A (2015). GHK-Cu peptide and skin regeneration. Biochimica et Biophysica Acta, 1850(8):1863–1885. PubMed

• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: Systematic Review (1993–2024). PMC Full Text

• ClinicalTrials.gov — investigational peptide research database. clinicaltrials.gov